Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Table 3 Multivariate analyses in the overall population

Variable	HR	95% CI	P*
OS
EBV	3.402	1.525–7.589	0.003
Cisplatin regimen	2.795	0.836–9.350	0.095
DFS
EBV	2.365	1.355–4.126	0.002
N stage	2.180	1.157–4.109	0.016
Cisplatin regimen	2.071	0.969–4.426	0.060

Abbreviations: OS overall survival, EBV Epstein–Barr virus, DFS disease-free survival, CI confidence interval, HR hazard ratio
*Chi-square test or Fisher’s exact test

ISSN: 1471-2407